

Pre
PCV22 unadj
Pre
PCV22/APA
PD1
PCV22 unadj
PD1
PCV22/APA
PD2
PCV22 unadj
PD2
PCV22/APA
PD3
PCV22 unadj
PD3
PCV22/APA
ECL Titer
10^7
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG. 1



PCV22/APA vs. PCV22 unadj
ECL Titer Ratio
100
10
1
0.1
0.01
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.2



Pre
PCV22 unadj
Pre
PCV22/APA
PD1
PCV22 unadj
PD1
PCV22/APA
PD2
PCV22 unadj
PD2
PCV22/APA
PD3
PCV22 unadj
PD3
PCV22/APA
OPA Titer
10^5
10^4
10^3
10^2
10^1
10^0
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.3



PCV22/APA vs. PCV22 unadj
OPA Titer Ratio
100
10
1
0.1
0.01
1 3 4 5 6A 6B 7F 9V 10A 12F 14 15A 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.4



PCV22 unadj
PCV22 APA
Naive
Survival (%)
110
100
90
80
70
60
50
40
30
20
10
0
48
72
96
120
144
168
Hours Post-Infection

FIG.5



Pre
PCV22 unadj
Pre
PCV22/APA
PD1
PCV22 unadj
PD1
PCV22/APA
PD2
PCV22 unadj
PD2
PCV22/APA
ECL GMT
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.6



PCV22/APA vs. PCV22 unadj
ECL GMT Ratio (95% CI)
100
10
1
0.1
0.01
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG. 7



Pre
PCV22 unadj
Pre
PCV22/APA
PD2
PCV22 unadj
PD2
PCV22/APA
OPA Titer
10^4
10^3
10^2
10^1
10^0
1
3
4
5
6A
6B
7F
9V
10A
12F
14
15A
15C
16F
18C
19A
19F
22F
23B
23F
33F
35B
Serotype

FIG.8



Pre
PD1
PD2
PD3
PCV23 unadj
ECL GMT
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
8
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.9A



PCV23(DMSO)/APA
Pre
PD1
PD2
PD3
ECL GMT
10^7
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
8
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.9B



PCV23(DMSO+Aq)/APA
Pre
PD1
PD2
PD3
ECL GMT
10^7
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
8
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.9C



Pre
PD1
PD2
PD3
PCV15/APA + PCV8/APA
ECL GMT
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
7F
8
9V
10A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.9D



▪ PCV23(DMSO)/APA vs. PCV23 unadj
● PCV23(DMSO+Aq)/APA vs. PCV23 unadj
ECL GMT Ratio (95% CI)
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.10A



■ PCV23(DMSO)/APA vs. PCV23 unadj
● PCV23(DMSO+Aq)/APA vs. PCV23 unadj
ECL GMT Ratio (95% CI)
1000
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.10B



■ PCV23(DMSO)/APA vs. PCV23 unadj
● PCV23(DMSO+Aq)/APA vs. PCV23 unadj
ECL GMT Ratio (95% CI)
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.10C



▪ PCV23(DMSO+Aq)/APA vs. PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
100
10
1
0.1
0.01
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.11A



■ PCV23(DMSO+Aq)/APA vs. PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
100
10
1
0.1
0.01
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG. 11B



▪ PCV23(DMSO+Aq)/APA vs. PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
100
10
1
0.1
0.01
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.11C



PCV23 unadj
PCV23(DMSO)/APA
PCV23(DMSO+Aq)/APA
PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
1000
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.12A



△ PCV23 unadj
□ PCV23(DMSO)/APA
◇ PCV23(DMSO+Aq)/APA
○ PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
10000
1000
100
10
1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG. 12B



■ PCV23 unadj
□ PCV23(DMSO)/APA
◇ PCV23(DMSO+Aq)/APA
○ PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
10000
1000
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG.12C



ECL GMT Ratio (95% CI)
1000
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype
△ PCV23 unadj
□ PCV23(DMSO)/APA
◇ PCV23(DMSO+Aq)/APA
○ PCV15/APA + PCV8/APA

FIG.12D



■ PCV23 unadj
□ PCV23(DMSO)/APA
◇ PCV23(DMSO+Aq)/APA
○ PCV15/APA + PCV8/APA
ECL GMT Ratio (95% CI)
100
10
1
0.1
1 3 4 5 6A 6B 7F 8 9V 10A 12F 14 15A 15B 15C 18C 19A 19F 22F 23B 23F 24F 33F 35B
Serotype

FIG. 12E



Pre
PD1
PD2
ECL GMT
10^7
10^6
10^5
10^4
10^3
10^2
10^1
1
3
4
5
6A
6B
6C
7F
8
9V
10A
11A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.13A



Pre
PD2 (D28)
OPA titer
10^0
10^1
10^2
10^3
10^4
10^5
1
3
4
5
6A
6B
6C
7F
8
9V
10A
11A
12F
14
15A
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.13B



Pre
PD1
PD2
PD3
ECL GMT
10^7
10^6
10^5
10^4
10^3
10^2
10^1
Serotype
1
3
4
5
6A
6B
6C
7F
8
9V
10A
11A
12F
14
15A
15B
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B

FIG. 14A



27/27
Pre
PD3 (D70)
OPA titer
10^0
10^1
10^2
10^3
10^4
10^5
1
3
4
5
6A
6B
7F
8
9V
10A
11A
12F
14
15A
15C
18C
19A
19F
22F
23B
23F
24F
33F
35B
Serotype

FIG.14B